Proprietary AI analyst is now available

Cannara Biotech Valuation Multiples

Discover Cannara Biotech's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Grown Rogue International, Ispire Technology, Ascend Wellness Holdings, Jushi Holdings and more.

Cannara Biotech Overview

About Cannara Biotech

Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .


Founded

2017

HQ

Canada

Employees

452

Website

cannara.ca

Financials (LTM)

Revenue: $85M
EBITDA: $22M

EV

$122M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Cannara Biotech Financials

Cannara Biotech reported last 12-month revenue of $85M and EBITDA of $22M.

In the same LTM period, Cannara Biotech generated $40M in gross profit, $22M in EBITDA, and $9M in net income.

Revenue (LTM)


Cannara Biotech P&L

In the most recent fiscal year, Cannara Biotech reported revenue of $76M and EBITDA of $20M.

Cannara Biotech is profitable as of last fiscal year, with gross margin of 44%, EBITDA margin of 27%, and net margin of 12%.

See analyst estimates for Cannara Biotech
LTMLast FY202320242025202620272028
Revenue$85M$76M$46M$64M$79M
Gross Profit$40M$33M$20M$25M$36M
Gross Margin48%44%43%39%46%
EBITDA$22M$20M$11M$14M$21M
EBITDA Margin26%27%25%22%26%
EBIT Margin19%21%16%14%19%
Net Profit$9M$9M$5M$6M$9M
Net Margin10%12%10%10%11%
Net Debt-$19M---

Financial data powered by Morningstar, Inc.

Cannara Biotech Stock Performance

Cannara Biotech has current market cap of $113M, and enterprise value of $122M.

Market Cap Evolution


Cannara Biotech's stock price is $1.14.

Cannara Biotech share price decreased by 5.6% in the last 30 days.

Cannara Biotech has an EPS (earnings per share) of $0.09.

See more trading valuation data for Cannara Biotech
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$122M$113M-1.9%-5.6%--$0.09

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Cannara Biotech Valuation Multiples

Cannara Biotech trades at 1.4x EV/Revenue multiple, and 5.5x EV/EBITDA.

See NTM and 2027E valuation multiples for Cannara Biotech

EV / Revenue (LTM)


Cannara Biotech Financial Valuation Multiples

As of June 23, 2026, Cannara Biotech has market cap of $113M and EV of $122M.

Cannara Biotech has a P/E ratio of 12.8x.

LTMLast FY202320242025202620272028
EV/Revenue1.4x1.6x2.6x1.9x1.5x
EV/EBITDA5.5x6.0x10.7x8.6x5.8x
EV/EBIT7.7x7.7x16.1x13.7x7.9x
EV/Gross Profit3.0x3.7x6.1x4.8x3.4x
P/E12.8x12.2x23.6x18.5x12.5x
EV/FCF13.9x12.6x(91.2x)25.7x12.9x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Cannara Biotech Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Cannara Biotech Margins & Growth Rates

Cannara Biotech grew revenue by 15% and EBITDA by 11% in the last fiscal year.

In the most recent fiscal year, Cannara Biotech reported gross margin of 44%, EBITDA margin of 27%, and net margin of 12%.

See estimated margins and future growth rates for Cannara Biotech

Cannara Biotech Margins

Last FY202420252026202720282029
Gross Margin44%39%46%48%
EBITDA Margin27%22%26%26%
EBIT Margin21%14%19%-
Net Margin12%10%11%12%
FCF Margin13%7%12%11%

Cannara Biotech Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth15%38%25%14%
Gross Profit Growth27%27%45%20%
EBITDA Growth11%23%48%14%
EBIT Growth-18%73%-
Net Profit Growth(6%)28%48%17%
FCF Growth(6%)(454%)100%5%

Data powered by FactSet, Inc. and Morningstar, Inc.

Cannara Biotech Operational KPIs

Cannara Biotech's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.0M for the same period.

Cannara Biotech's Rule of 40 is 40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Cannara Biotech's Rule of X is 62% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Cannara Biotech
LTMLast FY202320242025202620272028
Rule of 4039%40%---
Bessemer Rule of X60%62%---
Revenue per Employee-$0.2M---
Opex per Employee-$0.0M---
S&M Expenses to Revenue8%9%6%9%9%
G&A Expenses to Revenue9%12%17%15%12%
R&D Expenses to Revenue1%1%2%1%1%
Opex to Revenue-24%27%25%23%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Cannara Biotech Competitors

Cannara Biotech competitors include Grown Rogue International, Ispire Technology, Ascend Wellness Holdings, Jushi Holdings, Organigram Global, Aurora Cannabis, WM Tech, Planet 13, TerrAscend and MariMed.

Most Cannara Biotech public comparables operate across Cannabis, CannaTech and ViceTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Grown Rogue International3.8x-13.6x-
Ispire Technology0.7x1.0x(2.9x)(2218.4x)
Ascend Wellness Holdings1.3x1.4x5.7x5.9x
Jushi Holdings1.3x1.3x7.1x7.1x
Organigram Global0.7x0.6x10.3x8.9x
Aurora Cannabis0.5x0.5x3.0x3.4x
WM Tech0.1x0.1x0.3x0.4x
Planet 130.9x0.9x(9.1x)(14.6x)

This data is available for Pro users. Sign up to see all Cannara Biotech competitors and their valuation data.

Start Free Trial

Cannara Biotech VC Funding History

Before going public, Cannara Biotech raised $18M in total equity funding, across 1 round.


Cannara Biotech Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Jul-18Undisclosed stage-$18M-Cannara Biotech Inc. closed a $17.66 million CAD common share funding round on July 19, 2018, with First Republic Capital serving as sole broker. The financing was led by key opinion leaders in the cannabis industry and included participation from existing shareholder FSD Pharma, reinforcing their commitment to Cannara's strategic objectives. The proceeds were designated to support Phase 1 build-out of Cannara's Farnham facility in Quebec, as well as fund additional expansion and product development. The company positioned itself to develop one of the largest indoor medical cannabis growing facilities in North America, with plans to establish the Cannara brand as synonymous with high-quality medical cannabis through product branding and M&A activity.

Acquisitions by Cannara Biotech

Cannara Biotech has acquired 2 companies to date.

Last acquisition by Cannara Biotech was on May 5th 2026. Cannara Biotech acquired Medican Organic for $2M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Cannara Biotech

Medican Organic
shopCBD.com
Description
Medican Organic is a retail company that sells cannabis-related products.
shopCBD.com is a U.S. online retailer specializing in hemp-derived CBD products including oils, gummies, and topicals from brands like Charlotte's Web. Operating from Denver, it ships nationwide with lab-tested items compliant with 2018 Farm Bill standards.
HQ CountryCanadaUnited States
HQ City
Quebec City
Los Angeles, CA
Deal Date5 May 202626 May 2020
Valuation$2M$10M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Cannara Biotech acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Cannara Biotech

When was Cannara Biotech founded?Cannara Biotech was founded in 2017.
Where is Cannara Biotech headquartered?Cannara Biotech is headquartered in Canada.
How many employees does Cannara Biotech have?As of today, Cannara Biotech has over 452 employees.
Is Cannara Biotech publicly listed?Yes, Cannara Biotech is a public company listed on Tokyo Stock Exchange.
What is the stock symbol of Cannara Biotech?Cannara Biotech trades under LOVE ticker.
When did Cannara Biotech go public?Cannara Biotech went public in 2019.
Who are competitors of Cannara Biotech?Cannara Biotech main competitors include Grown Rogue International, Ispire Technology, Ascend Wellness Holdings, Jushi Holdings, Organigram Global, Aurora Cannabis, WM Tech, Planet 13, TerrAscend, MariMed.
What is the current market cap of Cannara Biotech?Cannara Biotech's current market cap is $113M.
What is the current revenue of Cannara Biotech?Cannara Biotech's last 12 months revenue is $85M.
What is the current revenue growth of Cannara Biotech?Cannara Biotech revenue growth (NTM/LTM) is 13%.
What is the current EV/Revenue multiple of Cannara Biotech?Current revenue multiple of Cannara Biotech is 1.4x.
What is the current EBITDA of Cannara Biotech?Cannara Biotech's last 12 months EBITDA is $22M.
What is Cannara Biotech's EBITDA margin?Cannara Biotech's last 12 months EBITDA margin is 26%.
What is the current EV/EBITDA multiple of Cannara Biotech?Current EBITDA multiple of Cannara Biotech is 5.5x.
What is the current FCF of Cannara Biotech?Cannara Biotech's last 12 months FCF is $9M.
What is Cannara Biotech's FCF margin?Cannara Biotech's last 12 months FCF margin is 10%.
What is the current EV/FCF multiple of Cannara Biotech?Current FCF multiple of Cannara Biotech is 13.9x.
How many companies Cannara Biotech has acquired to date?As of June 2026, Cannara Biotech has acquired 2 companies.
What was the largest acquisition by Cannara Biotech?$10M acquisition of shopCBD.com on 26th May 2020 was the largest M&A Cannara Biotech has done to date.
What companies Cannara Biotech acquired?Cannara Biotech acquired shopCBD.com and Medican Organic.
In how many companies Cannara Biotech has invested to date?Cannara Biotech hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Cannara Biotech

Lists including Cannara Biotech

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial